Journal
CHEM
Volume 4, Issue 7, Pages 1710-1725Publisher
CELL PRESS
DOI: 10.1016/j.chempr.2018.05.007
Keywords
-
Categories
Funding
- University of Bristol
- Engineering and Physical Sciences Research Council [EP/N024117/1]
- EPSRC [EP/N024117/1, EP/K03927X/1, EP/G007705/1] Funding Source: UKRI
- Engineering and Physical Sciences Research Council [EP/K03927X/1, EP/M022609/1, EP/J010588/1, EP/G007705/1] Funding Source: researchfish
Ask authors/readers for more resources
Differentiating nicotinic acetylcholine receptors (nAChR) to target the highaffinity nicotine alpha 4 beta 2 subtype is amajor challenge in developing effective addiction therapies. Although cytisine 1 and varenicline 2 (current smoking-cessation agents) are partial agonists of alpha 4 beta 2, these drugs display full agonism at the alpha 7 nAChR subtype. Site-specific modification of (-)-cytisine via Ir-catalyzed C. H activation provides access to C(10) variants 6-10, 13, 14, 17, 20, and 22, and docking studies reveal that C(10) substitution targets the complementary region of the receptor binding site, mediating subtype differentiation. C(10)modified cytisine ligands retain affinity for alpha 4 beta 2 nAChR and are partial agonists, show enhanced selectivity for alpha 4 beta 2 versus both alpha 4 beta 2 and alpha 7 subtypes, and critically, display negligible activity at alpha 7. Molecular dynamics simulations link the C(10) moiety to receptor subtype differentiation; key residues beyond the immediate binding site are identified, and molecular-level conformational behavior responsible for these crucial differences is characterized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available